Abstract | BACKGROUND: METHODS: RESULTS:
Anticancer agents were concomitantly given to 336 patients (58.3%) treated with apixaban and to 332 patients (57.3%) treated with dalteparin. In patients treated with apixaban, recurrent VTE occurred in 20 (6.0%) and 12 (5.0%) among patients treated or not treated with anticancer agents, respectively (hazard ratio [HR] = 1.14; 0.55-2.38); major bleeding occurred in 12 (3.6%) and 10 (4.2%) patients , respectively (HR = 0.79; 0.34-1.82), and death occurred in 74 (22.0%) and 61 (25.4%) patients , respectively (HR = 0.71; 0.51-1.00). In patients treated with dalteparin, recurrent VTE occurred in 24 (7.2%) and 22 (8.9%) among patients treated or not treated with anticancer agents, respectively (HR = 0.71; 0.40-1.28); major bleeding occurred in 16 (4.8%) and 7 (2.8%) patients, respectively (HR = 1.78; 0.66-4.79), and death occurred in 87 (26.2%) and 66 (26.7%) patients, respectively (HR = 0.85; 0.62-1.18). The comparative efficacy and safety of apixaban and dalteparin was not different in patients treated or not treated with anticancer agents. No effect on recurrent VTE, major bleeding or death was observed with inhibitors or inducers of P-glycoprotein and/or CYP3A4. CONCLUSION:
|
Authors | Melina Verso, Andres Munoz, Rupert Bauersachs, Menno V Huisman, Mario Mandalà, Giorgio Vescovo, Cecilia Becattini, Giancarlo Agnelli |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 148
Pg. 371-381
(05 2021)
ISSN: 1879-0852 [Electronic] England |
PMID | 33780665
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Pyrazoles
- Pyridones
- apixaban
- Dalteparin
|
Topics |
- Aged
- Anticoagulants
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Dalteparin
(administration & dosage)
- Drug Therapy, Combination
- Equivalence Trials as Topic
- Factor Xa Inhibitors
(administration & dosage)
- Female
- Follow-Up Studies
- Hemorrhage
(chemically induced, drug therapy)
- Humans
- Male
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Neoplasms
(drug therapy, pathology)
- Prognosis
- Pyrazoles
(administration & dosage)
- Pyridones
(administration & dosage)
- Venous Thromboembolism
(chemically induced, drug therapy)
|